Ligand Pharmaceuticals (LGND) Expected to Announce Quarterly Earnings on Thursday

Ligand Pharmaceuticals (NASDAQ:LGND) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Ligand Pharmaceuticals to post earnings of $1.23 per share and revenue of $37.84 million for the quarter.

Ligand Pharmaceuticals Price Performance

Shares of NASDAQ:LGND opened at $109.86 on Thursday. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 43.77 and a beta of 1.07. The company has a 50 day moving average of $108.10 and a 200-day moving average of $112.41. Ligand Pharmaceuticals has a one year low of $69.51 and a one year high of $129.90.

Insider Buying and Selling

In other Ligand Pharmaceuticals news, CFO Octavio Espinoza sold 5,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $115.03, for a total value of $575,150.00. Following the completion of the sale, the chief financial officer now directly owns 18,879 shares in the company, valued at $2,171,651.37. This represents a 20.94 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.90% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

LGND has been the subject of several recent research reports. StockNews.com upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 15th. Stifel Nicolaus began coverage on Ligand Pharmaceuticals in a research note on Thursday, April 10th. They issued a “buy” rating and a $143.00 target price on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $146.43.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.